IDH1 and glioblastoma: IDH wild-type (primary) GBM develops de novo in elderly (60–80 years) patients representing approximately the 90% of all cases of GBM, while IDH mutant (secondary) GBM is typical of younger people, has a more positive biomolecular pattern and is associated with a better prognosis [1].